BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Justin Chin

Session 2 – Pharma-biotech Partnering & Collaboration

Date:21 July (Wednesday)
Time:  12:20 – 13:50 (GMT+8)

Justin Chin

Company President
AstraZeneca Taiwan

Dr. Justin Chin is the Company President of AstraZeneca Taiwan, a global research-based pharmaceutical company, focused on Oncology, Cardiovascular, Renal, Metabolism and Respiratory diseases. He is also Standing Director of IRPMA; and Board Governor and Pharmaceutical Committee Co-Chair of AmCham Taiwan. He has more than 20 years of experience in the healthcare industry and has worked in Singapore, USA, China, Philippines and Taiwan. He is also a medical doctor with a background in public health.

Speech title & Synopsis

A.Catalyst to Biomedical Innovation- How AstraZeneca Supports Start-ups to Enhance Its Readiness to Expand into Global Market

AstraZeneca is a science-led biopharmaceutical company investing nearly 25 % of its total revenue in R&D, delivering a strong pipeline of new medicines. Our main R&D sites are based in Gaithersburg, US; Gothenburg, Sweden; and Cambridge, UK.  

Accelerating innovation lies at the core of AstraZeneca. Our global A.Catalyst network activates partnerships around the world for biomedical innovation – each hub contributes to our patient-centric goals by addressing unique unmet needs. As part of this network, AstraZeneca Taiwan supports Taiwan’s start-ups and promotes biomedical industry development in Taiwan.